摘要
1文献来源Cortes J,Cescon DW,Rugo HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple⁃negative breast cancer(KEYNOTE⁃355):A randomised,placebo⁃controlled,double⁃blind,phase 3 clinical trial[J].Lancet,2020,396(10265):1817-1828.
作者
张少华
张俊升
ZHANG Shao-hua;ZHANG Jun-sheng(Department of Oncology,Medical Cancer Center of Chinese PLA General Hospital,Beijing 100071,China)
出处
《循证医学》
2021年第2期76-78,共3页
The Journal of Evidence-Based Medicine
关键词
乳腺癌
三阴性
帕博利珠单抗
一线治疗
breast cancer
triple⁃negative
pembrolizumab
first⁃line treatment
